Not all efficient medical mixtures can be dissolved in water, some have undesirable side effects, and others are either deceptive or physiologically sensitive. In terms of bioactive normal composites, lipid-based nanoparticle structures (LBNP) are among the most promising colloidal transporters. The treatment of cancer has evolved thanks to the continued use of chemotherapeutic medicines, whose antitumor efficacy has been improved via research and development in oncology. LBNPs have several benefits, including their outstanding short-term and warm sufficiency, high stacking limit, simplicity of status, cheap collection expenses, and scalability of financial follow-through. Similar to how combining chemotherapeutic medications with lipid nanoparticles improves drug levels in diseased tissue while decreasing them in healthy tissue, it also reduces the potent healing portion and toxicity of the pharmaceuticals while simultaneously decreasing treatment resistance and lowering the drug levels in healthy tissue. Incredibly rigorous in vivo and in vitro testing of these LBNPs has shown exciting results in unequivocal clinical starts. This study highlights the recently developed LBNP varieties and their essential findings when utilized to cure malignant development, including major patient testing.